01 Sep LATEST NEWS: 4DMedical announces Phase Two of Australian clinical pilot program with I-MED Radiology Network
Medtech innovator 4DMedical announces Phase Two of Australian clinical pilot program with I-MED Radiology Network
Following successful completion of a comprehensive clinical pilot program conducted in collaboration with I-MED Radiology, Australia’s largest diagnostic imaging network, 4DMedical announces plans for a Phase Two program commencing immediately.
The Phase One pilot of 4DMedical’s unique XV Technology was conducted at an I-MED Radiology clinical site in Melbourne using existing medical imaging infrastructure. Valuable insights and important learnings were gained, following the input of I-MED specialist thoracic radiologists who were engaged to review and utilise XV LVAS reports as part of the clinical workflow.
Disease indication analysis during Phase One spanned conditions including post-COVID, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, sarcoidosis and silicosis.
At a macro level, the pilot confirmed the operational feasibility of 4DMedical’s XV Technology and provided I-MED with useful insights into clinical workflow.
“Patients involved in the Phase One pilot overwhelmingly reported a positive experience,” said I-MED’s General Manager Government Relations and External Partnerships, Mark Simpson. “Beyond the technical and clinical success of the program, I-MED is excited about the opportunities that this unique application offers in terms of delivering a superior service to patients presenting with lung disorders and their referring medical practitioners.”
I-MED Radiology operates 250 clinics located in all major metropolitan areas as well many regional communities across the country.
“Pilot Phase Two will be conducted at I-MED clinics in different states”, said 4DMedical’s Managing Director and Chief Executive Officer, Dr Andreas Fouras. “This will utilise a fluoroscopy suite from another manufacturer, further validating our market advantages of compatibility of equipment already in use worldwide and remote access to our cloud-based processing.”
XV Technology will be used to monitor patient treatment during Pilot Two with each patient being scanned twice, and initial scanning scheduled to occur across a four week period.